394 related articles for article (PubMed ID: 31266830)
1. Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV
Xiao R; An Y; Ye W; Derakhshan A; Cheng H; Yang X; Allen C; Chen Z; Schmitt NC; Van Waes C
Clin Cancer Res; 2019 Nov; 25(21):6463-6474. PubMed ID: 31266830
[TBL] [Abstract][Full Text] [Related]
2. ASTX660, a Novel Non-peptidomimetic Antagonist of cIAP1/2 and XIAP, Potently Induces TNFα-Dependent Apoptosis in Cancer Cell Lines and Inhibits Tumor Growth.
Ward GA; Lewis EJ; Ahn JS; Johnson CN; Lyons JF; Martins V; Munck JM; Rich SJ; Smyth T; Thompson NT; Williams PA; Wilsher NE; Wallis NG; Chessari G
Mol Cancer Ther; 2018 Jul; 17(7):1381-1391. PubMed ID: 29695633
[TBL] [Abstract][Full Text] [Related]
3. SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2.
Eytan DF; Snow GE; Carlson S; Derakhshan A; Saleh A; Schiltz S; Cheng H; Mohan S; Cornelius S; Coupar J; Sowers AL; Hernandez L; Mitchell JB; Annunziata CM; Chen Z; Van Waes C
Cancer Res; 2016 Sep; 76(18):5442-5454. PubMed ID: 27469115
[TBL] [Abstract][Full Text] [Related]
4. Death agonist antibody against TRAILR2/DR5/TNFRSF10B enhances birinapant anti-tumor activity in HPV-positive head and neck squamous cell carcinomas.
An Y; Jeon J; Sun L; Derakhshan A; Chen J; Carlson S; Cheng H; Silvin C; Yang X; Van Waes C; Chen Z
Sci Rep; 2021 Mar; 11(1):6392. PubMed ID: 33737574
[TBL] [Abstract][Full Text] [Related]
5. The non-peptidomimetic IAP antagonist ASTX660 sensitizes colorectal cancer cells for extrinsic apoptosis.
Knoll G; Ehrenschwender M
FEBS Open Bio; 2021 Mar; 11(3):714-723. PubMed ID: 33484626
[TBL] [Abstract][Full Text] [Related]
6. Next-generation hypomethylating agent SGI-110 primes acute myeloid leukemia cells to IAP antagonist by activating extrinsic and intrinsic apoptosis pathways.
Dittmann J; Haydn T; Metzger P; Ward GA; Boerries M; Vogler M; Fulda S
Cell Death Differ; 2020 Jun; 27(6):1878-1895. PubMed ID: 31831875
[TBL] [Abstract][Full Text] [Related]
7. LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus-negative Head and Neck Squamous Cell Carcinoma.
Yang L; Kumar B; Shen C; Zhao S; Blakaj D; Li T; Romito M; Teknos TN; Williams TM
Mol Cancer Ther; 2019 Jun; 18(6):1025-1035. PubMed ID: 31015310
[TBL] [Abstract][Full Text] [Related]
8. ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer.
Ye W; Gunti S; Allen CT; Hong Y; Clavijo PE; Van Waes C; Schmitt NC
Oncoimmunology; 2020; 9(1):1710398. PubMed ID: 32002309
[TBL] [Abstract][Full Text] [Related]
9. Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer.
Xiao R; Allen CT; Tran L; Patel P; Park SJ; Chen Z; Van Waes C; Schmitt NC
Oncoimmunology; 2018; 7(9):e1471440. PubMed ID: 30393585
[TBL] [Abstract][Full Text] [Related]
10. Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.
Tanaka N; Patel AA; Wang J; Frederick MJ; Kalu NN; Zhao M; Fitzgerald AL; Xie TX; Silver NL; Caulin C; Zhou G; Skinner HD; Johnson FM; Myers JN; Osman AA
Clin Cancer Res; 2015 Nov; 21(21):4831-44. PubMed ID: 26124202
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism.
Bullenkamp J; Raulf N; Ayaz B; Walczak H; Kulms D; Odell E; Thavaraj S; Tavassoli M
Cell Death Dis; 2014 Oct; 5(10):e1489. PubMed ID: 25341043
[TBL] [Abstract][Full Text] [Related]
12. Cellular inhibitor of apoptosis 1 (cIAP-1) degradation by caspase 8 during TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis.
Guicciardi ME; Mott JL; Bronk SF; Kurita S; Fingas CD; Gores GJ
Exp Cell Res; 2011 Jan; 317(1):107-16. PubMed ID: 20951133
[TBL] [Abstract][Full Text] [Related]
13. Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer.
Crawford N; Stott KJ; Sessler T; McCann C; McDaid W; Lees A; Latimer C; Fox JP; Munck JM; Smyth T; Shah A; Martins V; Lawler M; Dunne PD; Kerr EM; McDade SS; Coyle VM; Longley DB
Mol Cancer Ther; 2021 Sep; 20(9):1627-1639. PubMed ID: 34389694
[TBL] [Abstract][Full Text] [Related]
14. Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein.
Karikari CA; Roy I; Tryggestad E; Feldmann G; Pinilla C; Welsh K; Reed JC; Armour EP; Wong J; Herman J; Rakheja D; Maitra A
Mol Cancer Ther; 2007 Mar; 6(3):957-66. PubMed ID: 17339366
[TBL] [Abstract][Full Text] [Related]
15. Combination effects of SMAC mimetic birinapant with TNFα, TRAIL, and docetaxel in preclinical models of HNSCC.
Eytan DF; Snow GE; Carlson SG; Schiltz S; Chen Z; Van Waes C
Laryngoscope; 2015 Mar; 125(3):E118-24. PubMed ID: 25431358
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Small Molecules Target Inhibitor of Apoptosis Proteins in Cancers with Deregulation of Extrinsic and Intrinsic Cell Death Pathways.
Derakhshan A; Chen Z; Van Waes C
Clin Cancer Res; 2017 Mar; 23(6):1379-1387. PubMed ID: 28039268
[TBL] [Abstract][Full Text] [Related]
17. Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression.
Strekalova E; Malin D; Rajanala H; Cryns VL
Breast Cancer Res Treat; 2017 Jun; 163(3):435-447. PubMed ID: 28324269
[TBL] [Abstract][Full Text] [Related]
18. Tumor necrosis factor‑related apoptosis‑inducing ligand as a therapeutic option in urothelial cancer cells with acquired resistance against first‑line chemotherapy.
Vallo S; Stege H; Berg M; Michaelis M; Winkelmann R; Rothweiler F; Cinatl J
Oncol Rep; 2020 Apr; 43(4):1331-1337. PubMed ID: 32020226
[TBL] [Abstract][Full Text] [Related]
19. A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H,2 H,3 H-pyrrolo[3,2- b]pyridin-1-yl)-2-[(2 R,5 R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660).
Johnson CN; Ahn JS; Buck IM; Chiarparin E; Day JEH; Hopkins A; Howard S; Lewis EJ; Martins V; Millemaggi A; Munck JM; Page LW; Peakman T; Reader M; Rich SJ; Saxty G; Smyth T; Thompson NT; Ward GA; Williams PA; Wilsher NE; Chessari G
J Med Chem; 2018 Aug; 61(16):7314-7329. PubMed ID: 30091600
[TBL] [Abstract][Full Text] [Related]
20. Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells.
Engesæter BO; Sathermugathevan M; Hellenes T; Engebråten O; Holm R; Flørenes VA; Mælandsmo GM
Cancer Biol Ther; 2011 Jul; 12(1):47-58. PubMed ID: 21508672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
